Our client, a global leader in the rare disease space, is seeking novel strategies for tissue-specific drug delivery to the central nervous system (CNS), bone, connective tissue/cartilage, skeletal muscle, kidney and heart tissues. Key target cell types include (but are not limited to): CNS – neurons, microglia and astrocytes, muscle – myofibers and satellite cells, kidney – podocytes and tubular epithelial cells, bone and cartilage – mesenchymal stem cells, osteo- and chondro- progenitor cells and osteoblasts.
Approaches should be capable of delivering...